Blaztere 4 Mg Injection (Zoledronic Acid)
Price range: $155.47 through $391.35Required
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 2 Injection | $155.47 | $77.74 / injection | ||
| 4 Injection | $274.92 | $68.73 / injection | ||
| 6 Injection | $391.35 | $65.23 / injection |
About Blaztere 4 Mg Injection (Zoledronic Acid)
Medicine information
- Active ingredient
- Zoledronic acid
- Delivery time
- 14-21 business days after dispatch for destinations covered by the Rest of World delivery framework, including India; this is an estimate and customs or local carrier delays may extend transit. Cheap_Generic_Med_Shipping_Coun…
- Indication
- Treatment of hypercalcemia caused by malignancy and treatment of patients with multiple myeloma or documented bone metastases from solid tumors, together with standard anticancer therapy.
- Manufacturer
- Dr. Reddy's Laboratories Ltd.
- Packaging
- 1 vial
- Strength
- 4 mg
- Dosage form
- Lyophilized powder for solution for intravenous infusion
- Route
- Intravenous infusion
Medicine overview
Blaztere 4 Mg Injection contains zoledronic acid, a bisphosphonate medicine that acts on bone. The verified Blaztere formulation contains 4 mg of zoledronic acid in a vial and is intended for preparation and administration by intravenous infusion. It is used for cancer-related high blood calcium and for bone complications associated with multiple myeloma or solid tumors that have spread to bone. Because kidney function, calcium levels, hydration and dental health can affect treatment safety, clinical assessment and monitoring are important.
What it is used for
Blaztere 4 Mg Injection is used to treat hypercalcemia of malignancy, meaning abnormally high blood calcium caused by cancer. Zoledronic acid 4 mg is also used with standard anticancer treatment in patients with multiple myeloma and in patients who have documented bone metastases from solid tumors. In prostate cancer, prescribing information specifies use where the disease has progressed after at least one hormonal therapy.
How it works
Zoledronic acid belongs to the bisphosphonate class. It has a strong affinity for mineralized bone and inhibits osteoclast-mediated bone resorption—the process in which specialized cells break down bone. Reducing this excessive bone breakdown can lower calcium released from bone into the bloodstream and helps reduce skeletal complications associated with cancer affecting the bones. Its effects on bone can persist because bisphosphonates bind to bone tissue.
How it is taken
Blaztere is administered intravenously by a healthcare professional after appropriate preparation of the vial contents. Zoledronic acid 4 mg used for cancer-related indications must be given as an intravenous infusion over no less than 15 minutes; it must not be given as a rapid direct injection. Kidney function should be assessed before treatment, and patients with hypercalcemia of malignancy should be adequately hydrated. The prescribed amount and treatment interval depend on the indication and renal function.
Important warnings
Do not use zoledronic acid in patients with known hypersensitivity to zoledronic acid or formulation components. Kidney injury, including renal failure, can occur; renal function should be checked before treatment and caution is required with renal impairment, dehydration and nephrotoxic medicines. Hypocalcemia must be corrected before treatment, with calcium and vitamin D supplementation as clinically appropriate. Osteonecrosis of the jaw has been reported, particularly in cancer patients, so a preventive dental examination is recommended before treatment and invasive dental procedures should generally be avoided during therapy when possible. Severe bone, joint or muscle pain and atypical femoral fractures can occur. Aminoglycosides, calcitonin and loop diuretics may increase the risk of low calcium, while other nephrotoxic medicines can increase renal risk. Patients should not receive another zoledronic-acid product or another bisphosphonate concurrently unless specifically directed.
Side effects and monitoring
Common reported effects include nausea, fatigue, anemia, bone pain, constipation, fever, vomiting and shortness of breath. An acute-phase reaction can occur within the first few days after an infusion, causing fever, chills, fatigue, muscle or joint aches and flu-like symptoms. Serious or less common problems include kidney impairment, severe hypocalcemia, osteonecrosis of the jaw, severe musculoskeletal pain, atypical femoral fractures, eye inflammation and serious hypersensitivity reactions. Serum creatinine should be checked before treatment, with calcium and other relevant electrolytes monitored as clinically indicated. Seek prompt medical attention for reduced urine output, severe weakness or muscle spasms, seizures, facial or throat swelling, breathing difficulty, persistent jaw pain or non-healing mouth sores, or new unexplained thigh or groin pain.
Pregnancy
Zoledronic acid can cause fetal harm based on its mechanism of action and animal data. Pregnancy status should be checked before starting treatment in patients who could become pregnant, and effective contraception is advised during and after treatment. Zoledronic acid remains bound to bone and may be released for an extended period.
Breastfeeding
Breastfeeding is not recommended during and after zoledronic acid treatment. It is not known whether zoledronic acid passes into human milk, but the medicine binds to bone for a prolonged period and serious adverse effects in a breastfed child are considered possible.
Food and drink
No food interaction is relevant to administration because Blaztere is given by intravenous infusion rather than taken by mouth. Patients treated for hypercalcemia of malignancy should be adequately hydrated before administration, while fluid management should be individualized in patients at risk of heart failure or fluid overload.
Frequently asked questions
Will I feel flu-like after my first zoledronic acid infusion?
It can happen. Fever, chills, tiredness, muscle aches, joint aches and other flu-like symptoms can develop within the first few days after an infusion and usually settle within several days. Contact your healthcare team if symptoms are severe or persistent.
Why does my dentist need to know before I receive Blaztere?
Zoledronic acid has been associated with osteonecrosis of the jaw, a rare but serious problem in which jawbone does not heal normally. A preventive dental examination is recommended before treatment, and good dental care remains important during therapy.
Can Blaztere affect my kidneys?
Yes. Zoledronic acid can impair kidney function, particularly when other risk factors are present. Kidney function should be assessed before treatment, and the infusion should be administered over at least 15 minutes.
Why are calcium levels checked with zoledronic acid?
Zoledronic acid can lower blood calcium, sometimes severely. Existing hypocalcemia should be corrected before treatment, and calcium and other electrolytes may need monitoring during therapy.
How long does a Blaztere infusion take?
Zoledronic acid 4 mg for these cancer-related indications should be administered by intravenous infusion over no less than 15 minutes. The medicine is given by a healthcare professional rather than self-injected.
What symptoms should I report after treatment?
Seek medical advice for symptoms such as markedly reduced urination, severe muscle cramps or spasms, seizures, persistent jaw pain or non-healing mouth sores, or new unexplained thigh or groin pain. Facial or throat swelling or difficulty breathing requires urgent medical attention.
Can Cheap Generic Med ship Blaztere to the United States?
Cheap Generic Med serves the United States under its international shipping model. Delivery is typically estimated at 10-14 business days after dispatch, although customs or carrier delays can extend transit. Prescription and personal-import requirements may apply.
Will my Cheap Generic Med order have tracking?
Under the standard international fulfilment model, tracked shipping is used and a tracking number should be provided after dispatch. Tracking may take 24-72 hours to begin showing movement in the carrier system.
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Active Ingredients | Zoledronic acid (4Mg) |
|---|---|
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packaging | Qty |
| strength | 4mg |
| Delivery Time | 6 To 15 days |
Related products
Duvadilan Retards 40 Mg (Isoxsuprine Hcl)
Folvite Active Capsule (L-Methylfolate)
Reviews
There are no reviews yet.